ClinicalTrials.gg
CompletedNCT02261532Updated Nov 14, 2024Results posted

A Phase I Study of TAS-102 in Solid Tumors

A Phase 1 interventional study of TAS-102 in Advanced or Metastatic Solid Tumors, sponsored by Taiho Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-14.

Sponsored by Taiho Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The primary objective of this study is to evaluate the pharmacokinetics of TAS-102 after single and multiple dose in Chinese patients with solid tumor.

Read the detailed description

This is an open-label, non-randomized, single group Phase 1 study of TAS-102, evaluating the pharmacokinetics, safety, and antitumor activity. Blood sampling will be performed during the first cycle (Day1 and Day 12) of therapy in all consenting patients.

02

Conditions studied

  • Advanced or Metastatic Solid Tumors
03

In context

Lead sponsor

Taiho Pharmaceutical Co., Ltd. is the lead sponsor of 43 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Has provided written prior to performance of any study procedure.
    1. Has definitive or cytologically confirmed advanced or solid tumor.
    1. Is able to take medications orally.
    1. Has adequate organ function (bone marrow, kidney and liver).
    1. Has Eastern Cooperative Group () performance status of 0 or 1.

Exclusion criteria

Exclusion Criteria:

    1. Has received TAS-102.
    1. Has suffered serious complications.
    1. Has unresolved toxicity of greater than or equal to Grade 2 attributed to any prior therapies.
    1. Has had prior gastrectomy.
    1. Is a pregnant or lactating female or male who refused using during the clinical trial period and within 6 months after discontinuation of study treatment.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    TAS-102

    Drug: TAS-102

Interventions

  • DrugTAS-102

    TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.

06

What researchers measure

Primary outcomes

  1. Cmax (Maximum Plasma Concentration) of FTD

    Time frame: Multiple time points on Day 1 and Day 12 of Cycle 1.

  2. Tmax (Time to Reach Maximum Drug Concentration in Blood) of FTD

    Time frame: Multiple time points on Day 1 and Day 12 of Cycle 1.

  3. AUC0-t (Area Under the Plasma Concentration Versus Time Curve From Time 0 to Time (t) of the Last Quantifiable Concentration ) of FTD

    Time frame: Multiple time points on Day 1 and Day 12 of Cycle 1.

07

Results

Posted Oct 18, 2024

Participant flow

Participant flow — Overall Study
MilestoneTAS-102
Started15
Completed15
Not completed0

Outcome measures

PrimaryCmax (Maximum Plasma Concentration) of FTD
Time frame:
Multiple time points on Day 1 and Day 12 of Cycle 1.
Reported as:
Geometric mean · ng/mL
Cmax (Maximum Plasma Concentration) of FTD
ng/mLTAS-102
Day 13019.49 ± 34.0
Day 123693.08 ± 21.7
PrimaryTmax (Time to Reach Maximum Drug Concentration in Blood) of FTD
Time frame:
Multiple time points on Day 1 and Day 12 of Cycle 1.
Reported as:
Geometric mean · hours
Tmax (Time to Reach Maximum Drug Concentration in Blood) of FTD
hoursTAS-102
Day 11.00 ± 58.7
Day 122.61 ± 36.2
PrimaryAUC0-t (Area Under the Plasma Concentration Versus Time Curve From Time 0 to Time (t) of the Last Quantifiable Concentration ) of FTD
Time frame:
Multiple time points on Day 1 and Day 12 of Cycle 1.
Reported as:
Geometric mean · ng·hr/mL
AUC0-t (Area Under the Plasma Concentration Versus Time Curve From Time 0 to Time (t) of the Last Quantifiable Concentration ) of FTD
ng·hr/mLTAS-102
Day 17796.60 ± 19.1
Day 1218181.34 ± 30.0

Adverse events

Collected over 15 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TAS-1020/15 (0%)4/15 (26.7%)14/15 (93.3%)
Most frequent serious events
Most frequent serious events
EventTAS-102
AnaemiaBlood and lymphatic system disorders1/15
NauseaGastrointestinal disorders1/15
Small intestinal obstructionGastrointestinal disorders1/15
VomitingGastrointestinal disorders1/15
FatigueGeneral disorders1/15
Platelet count decreasedInvestigations1/15
Bone painMusculoskeletal and connective tissue disorders1/15
DizzinessNervous system disorders1/15
HeadacheNervous system disorders1/15
Most frequent other events
Showing 10 of 45
Most frequent other events
EventTAS-102
NauseaGastrointestinal disorders12/15
VomitingGastrointestinal disorders9/15
FatigueGeneral disorders7/15
Decreased appetiteMetabolism and nutrition disorders7/15
ConstipationGastrointestinal disorders5/15
LeukopeniaBlood and lymphatic system disorders5/15
NeutropeniaBlood and lymphatic system disorders5/15
Neutrophil count decreasedInvestigations4/15
White blood cell count decreasedInvestigations4/15
DiarrhoeaGastrointestinal disorders3/15

Baseline characteristics

Age, Continuous
Age, Continuous(years)TAS-102
Median56.0 (35 to 64)
Sex: Female, Male
Sex: Female, Male(Participants)TAS-102
Female3
Male12
Region of Enrollment
Region of Enrollment(participants)TAS-102
China15
08

Study locations

1 site
  • Taiho Pharmaceutical Co., Ltd selected site
    Beijing, China
09

References and documents

Publications

  • Wang X, Zhou J, Li Y, Ge Y, Zhou Y, Bai C, Shen L. Pharmacokinetics, Safety, and Preliminary Efficacy of Oral Trifluridine/Tipiracil in Chinese Patients with Solid Tumors: A Phase 1b, Open-Label Study. Clin Pharmacol. 2020 Apr 9;12:21-33. doi: 10.2147/CPAA.S232104. eCollection 2020. PubMed 32308505 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2014 to primary completion in Oct 2015, 13 months.

Results were first posted in Oct 2024, 9 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2014
First posted
Oct 10, 2014
StartActual
Sep 2014
Primary completionActual
Oct 2015
CompletionActual
Jun 2017
Results first posted
Oct 18, 2024
Last update
Nov 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02261532
Responsible party
Sponsor
First posted
Oct 10, 2014
Start date
Sep 2014
Primary completion
Oct 2015
Completion
Jun 2017
Results posted
Oct 18, 2024
Last update
Nov 14, 2024

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion